StockData

IRulya Therapeutics Inc. (IRLA) stock

IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$38.45+1.09 (+2.92%)

Close on Nov 17, 2026Market cap $39.11MP/E –Yield –

IRulya Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

IRulya Therapeutics's price to book ratio was 20.6× on Jul 31, 2026, against 42.3× a year earlier. Over the last 5 years it ranged from 4.4× to 402.0×, with a median of 18.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Jul 31, 202620.6×−130.2
2025Oct 31, 2025150.8×+114.8
2024Dec 31, 202436.0×+26.8
2023Dec 29, 20239.2×+4.8
2022Dec 30, 20224.4×−52.4
2021Dec 31, 202156.8×−30.3
2020Dec 31, 202087.2×−149.6
2019Dec 31, 2019236.8×–

More IRulya Therapeutics figures

See a number that looks wrong?